Eli Lilly and major shareholder Sells $14,156,500 in Stock (LLY)
Eli Lilly and (NYSE:LLY) major shareholder Lilly Endowment Inc sold 230,000 shares of the company’s stock on the open market in a transaction dated Friday, June 20th. The stock was sold at an average price of $61.55, for a total transaction of $14,156,500.00. Following the sale, the insider now directly owns 134,070,804 shares of the company’s stock, valued at approximately $8,252,057,986. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
LLY has been the subject of a number of recent research reports. Analysts at Morgan Stanley reiterated an “underweight” rating on shares of Eli Lilly and in a research note on Monday, June 2nd. They now have a $48.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly and in a research note on Friday, May 16th. They now have a $61.00 price target on the stock. Finally, analysts at Argus reiterated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, April 29th. They now have a $64.00 price target on the stock. Three analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $60.46.
Shares of Eli Lilly and (NYSE:LLY) traded up 0.06% during mid-day trading on Monday, hitting $62.07. The stock had a trading volume of 5,103,437 shares. Eli Lilly and has a 1-year low of $47.53 and a 1-year high of $62.14. The stock’s 50-day moving average is $59.40 and its 200-day moving average is $56.47. The company has a market cap of $66.582 billion and a P/E ratio of 17.34.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.70 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.70. The company had revenue of $4.68 billion for the quarter, compared to the consensus estimate of $4.78 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. The company’s quarterly revenue was down 16.4% on a year-over-year basis. On average, analysts predict that Eli Lilly and will post $2.78 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.16%. The ex-dividend date of this dividend is Wednesday, August 13th.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.